[Alpha Biz= Kim Jisun] SLS Bio announced on June 9 that it has temporarily suspended its operations in the "pharmaceutical quality testing (excluding quasi-drugs)" segment, following a regulatory notice. The suspension affects business worth approximately KRW 5.9 billion, accounting for about 70% of the company’s total revenue in the previous year.
The company explained that the suspension resulted from a failure to meet standards in one of ten test items used to evaluate researchers’ competency, as assessed by the relevant licensing authority.
As part of its response, SLS Bio plans to request a re-evaluation from the Ministry of Food and Drug Safety (MFDS) and will enhance its researcher competency evaluation system to meet regulatory expectations. The suspension is expected to last up to two to three weeks, depending on the re-evaluation schedule.
SLS Bio is responsible for the quality control of Wegovy, a weight-loss drug.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
